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Abstract
Introduction: Among patients with bacteraemia or sepsis the plasma cell-free DNA (cf-DNA) biomarker has prognostic value
and Pitt bacteraemia scores predict outcome. We evaluated the prognostic value of plasma cf-DNA in patients with
Staphylococcus aureus bacteraemia (SAB) treated in the ICU or in the general ward.
Methods: 418 adult patients with positive blood culture for S. aureus were prospectively followed for 90 days. SAB patients
were grouped according to ICU treatment: 99 patients were treated in ICU within 7 days of documented SAB whereas 319
patients were managed outside ICU. Pitt bacteraemia scores were assessed at hospital arrival and cf-DNA was measured at
days 3 and 5 from positive blood culture.
Results: SAB patients with high Pitt bacteraemia scores and ICU treatment presented higher cf-DNA values as compared to
SAB patients with low Pitt bacteraemia scores and non-ICU treatment at both days 3 and 5. Among ICU patients cf-DNA
.1.99 mg/ml at day 3 predicted death with a sensitivity of 67% and a specificity of 77% and had an AUC in receiver
operating characteristic analysis of 0.71 (p,0.01). The cut-off cf-DNA .1.99 mg/ml value demonstrated a strong association
to high Pitt bacteraemia scores ($4 points) (p,0.000). After controlling for all prognostic markers, Pitt bacteraemia scores
$4 points at hospital admission (OR 4.47, p,0.000) and day 3 cf-DNA (OR 3.56, p,0.001) were the strongest factors
significantly predicting outcome in ICU patients. cf-DNA at day 5 did not predict fatal outcome.
Conclusion: High cf-DNA concentrations were observed among patients with high Pitt bacteraemia scores and ICU
treatment. Pitt bacteraemia scores ($4 points) and cf-DNA at day 3 from positive blood culture predicted death among SAB
patients in ICU and were found to be independent prognostic markers. cf-DNA had no prognostic value among non-ICU
patients.
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Introduction
Staphylococcus aureus accounts for one fourth or one fifth of all
bacteraemic infections worldwide [1,2,3,4]. It is among the three
most common pathogens in all types of infections in critically ill
patients [5]. S. aureus bacteraemia (SAB) is commonly found also in
previously healthy individuals and it is associated with high 7–39%
overall mortality [6,7,8]. Up to one third of SAB patients need
treatment in intensive care unit (ICU) [9,10].
Biomarkers and intensive care scoring systems have been
studied as clinical tools in the evaluation of severely ill patients
with bacteraemia or sepsis and they may be used as an aid in risk
stratification or as a surrogate marker for patient outcome, to
identify a patient with increased probability of having a disease or
a pathologic process, or to follow the treatment response
[11,12,13,14]. Several scoring systems e.g. the Acute Physiology
and Chronic Health Evaluation II (APACHE II) or SOFA score
(sequential organ failure assessment) are available for assessing
severity of illness and predicting outcome among ICU patients
[13,14]. The Pitt bacteraemia score system is known to reflect
severity of illness among SAB patients [15,16] and the Pitt
bacteraemia scores system was recently demonstrated to better
predict mortality among ICU patients with sepsis as compared to
APACHE II [12].
Cell-free DNA (cf-DNA) is a biomarker that has received a lot of
attention in the research of critically ill patients recently
[17,18,19,20,21,22]. The term cf-DNA implies free DNA
fragments in the plasma originating from necrosis and apoptotic
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cells [23]. Healthy individuals display low levels of cf-DNA in
plasma [24] as phagocytes remove deceased cell debris [25].
Prediction of sepsis development among both critically ill patients
[17] and in hospitalized patients [20] has been reflected by
elevated cf-DNA levels. Sepsis is known to enhance apoptosis [26]
and cell necrosis [27] and to lead to elevated cf-DNA levels
[25,28]. Plasma cf-DNA upon ICU admission has been shown to
independently correlate with serum lactate elevation among
patients with severe sepsis and septic shock. This may reflect the
impact of sepsis related hypoxemia on apoptosis [19]. Non-
survivors in ICU have been shown to have higher cf-DNA levels
than survivors [17,18,19,20,29,30]. High cf-DNA has been shown
to be an independent prognostic marker for fatal outcome among
bacteraemic patients [21]. Recently, a thorough retrospective
study showed a very high discriminative capability of cf-DNA to
predict mortality among ICU patients with severe sepsis [30].
The capability of cf-DNA to predict infection, sepsis and
mortality has been evaluated in several studies
[17,19,20,21,22,29,30]. However, the usefulness of cf-DNA
measurement in bacteraemic patients has been evaluated only in
a few studies including several different bacteraemic pathogens
with higher cf-DNA levels observed in ICU treated patients [21]
and in non-surviving severe sepsis patients in ICU [30]. The
prognostic use and cut-off values of cf-DNA regarding bacteraemic
ICU patients with only one causative organism has not been
studied. The aim of our study was to evaluate and compare the
prognostic value of cf-DNA, and its correlation to Pitt bacteraemia
scores, in SAB patients with ICU treatment and in SAB patients
managed without ICU treatment. We observed that cf-DNA levels
correlated significantly with Pitt bacteraemia scores and both were
independent predictors for death in SAB patients requiring ICU
surveillance whereas cf-DNA had no outcome predictive value
among SAB patients managed without ICU treatment.
Patient Cohort and Methods
Ethics statement
The trial was approved by The institutional review board of Helsinki
University Central Hospital and
The Ethical committee of Helsinki University Central Hospital and by
each study site and a written informed consent was provided by
each patient [31].
Settings and study population
Adult patients with at least one positive blood culture for S. aureus
were included from five university and seven central hospitals in
Finland from January 1999 to May 1999 and January 2000 to
August 2002. Altogether 430 SAB patients were included and
followed prospectively for at least 90 days [31]. The median time
between blood culture sampling and study inclusion was three days.
Exclusion criteria included: age ,18 years, pregnancy, breastfeed-
ing, imprisonment, epilepsy, bacteraemia 28 days prior to the study,
polymicrobial bacteraemia and meningitis [31]. All cases of
methicillin-resistant S. aureus (MRSA) were excluded (N = 6). We
documented data regarding gender, age, acquisition of SAB,
underlying diseases and McCabe’s classification, ICU treatment,
parameters required for Pitt bacteraemia score calculation i.e.
mental status, vital signs, requirement for mechanical ventilation,
and recent cardiac arrest [32], acute liver of kidney failure, deep
infection focus and laboratory findings including plasma cf-DNA
and C-reactive protein (CRP) concentrations at days 3 and 5 from
the positive blood culture sampling. Primary endpoint was regarded
as mortality at 7, 28 or 90 days. Secondary end points were deep
infection foci localized during the 90 days follow-up.
Follow-up time period
None of the patients were lost during the follow-up of 90 days.
Patients that were transferred to other hospitals were followed
from patient records and direct contact to that hospital. Patients
who were not hospitalized at 90 days had a follow-up visit at the
outpatient policlinic.
Definitions
SAB was regarded as healthcare-associated (HA) when the
positive blood culture for S. aureus was obtained $48 h after
hospital admission or when the patient had remained in a long-
term care facility or undergone haemodialysis within the preceding
two months. McCabe’s criteria were used to classify underlying
diseases [33]. Deep infection foci included mediastinitis, pneumo-
nia, endocarditis, purulent arthritis, osteomyelitis, deep-seated
abscess, and any foreign-body infection. Deep infection foci were
documented either based on clinical suspicion or verified by
bacteriological, radiological or pathological findings. Severe sepsis
was classified as sepsis in combination with hypotension,
hypoperfusion, or organ failure [34]. Complicated SAB was
defined as SAB in combination with deep infection foci, severe
sepsis, septic shock or high Pitt bacteraemia scores .4. Patients
who needed ICU treatment within 7 days of positive blood culture
were classified as ICU patients.
Cell-free DNA and C-reactive protein analysis
Plasma samples for cf-DNA and CRP measurements were taken
on days 3 and 5 after blood culture collection as explained above
and immediately frozen to minus 70 degrees Celsius. Quant-iTTM
high-sensitivity DNA assay kit and QubitH fluorometer (Invitro-
gen, Carlsbad, CA, USA) were used to determine cf-DNA from
plasma [21]. Manufacturer’s directives were followed at each
laboratory step. The intra-day variation coefficients at mean cf-
DNA levels of 0.734 mg/ml, 1.377 mg/ml and 4.954 mg/ml
were 1.8%, 4.3% and 1.7%, respectively and the corresponding
inter-day variation coefficients were 3.8%, 5.0% and 3.2%,
respectively [21]. Serum or plasma C-reactive protein (CRP)
(use of plasma instead of serum began 18.3.2002) was subjected to
automatic immunoturbidometric analysis using analysers 917 or
Modular PP-analyser (Hitachi Ltd, Tokyo, Japan) and Tina-quant
CRP reagents (Roche Diagnostics, Tina-quant CRP). The normal
value of CRP concentration was ,10 mg/L for both methods.
Statistical analysis
Data is presented either as absolute values and percentages or as
median and interquartile ranges (IQR, 25th and 75th percentiles).
Pearson’s X2 -test was used to compare categorical variables
whereas Mann-Whitney U-test was used for nonparametric data.
Odds ratios (OR) with 95% confidence intervals (CI) were
calculated. Receiver operating characteristic (ROC) curves were
used to evaluate the discriminative power of cf-DNA in predicting
90-day mortality. The area under the curve (AUC) was calculated
for each ROC curve. ROC-curves were drawn for cf-DNA and
CRP. Univariate factors with p,0.1 were entered into a Cox
regression model (proportional hazards regression) for analysis of
factors predicting 90 days mortality. Analyses were done using
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA). All tests were
two-tailed and p,0.05 was considered as significant. Youden
index was defined as the sensitivity and specificity sum with the
highest value or the ROC-curve point equally maximising both
sensitivity and specificity values to locate the cut-off point.
Cf-DNA, Pitt Scores, ICU and S.aureus Bacteraemia
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e87741
Results
Patient characteristics and cf-DNA concentrations
Altogether 430 SAB patients were included into the study but
due to missing plasma samples the results of 418 patients are
shown. All patients received an effective antibiotic in vitro against
their S. aureus blood isolate starting from the day of the positive
blood culture. The majority of patients (76%) received a beta-
lactam antibiotic. Vancomycin was used only in 2% of the patients
and it was the only anti-microbial agent in 1% of patients.
The median cf-DNA concentrations at days 3 and 5 from the
positive blood culture are shown in Table 1 stratified according to
patient characteristics. At day 3, patient demographics or
underlying conditions had no significant effect on the cf-DNA
levels whereas at day 5, male gender (p,0.000), age over 60 years
(p,0.05), alcoholism (p,0.05), diabetes (p,0.05) and coronary
artery disease (p,0.01) were all associated with significantly higher
cf-DNA concentrations. The lack of severe underlying diseases (i.e.
McCabe’s classification of healthy or nonfatal diseases) was
associated to significantly lower cf-DNA values as compared to
patients without these characteristics. Patients with chronic renal
failure, dialysis treatment, rheumatoid or connective tissue diseases
or malignancies did not present higher cf-DNA concentrations at
neither 3 or at 5 days (Table 1). The cf-DNA concentrations at
both days 3 and 5 correlated significantly with high Pitt
bacteraemia scores ($4 points). cf-DNA concentrations both at
days 3 and 5 were significantly higher in ICU patients, in patients
with a deep infection focus and in those who died as compared to
patients without these factors (Table 1).
ICU treatment
ICU patients had significantly more often alcoholism and a deep
infection focus, and their mortality was significantly higher at 7, 28
and 90 days from the documented SAB as compared to non-ICU
patients (data not shown). ICU non-survivors within 7 days of
documented SAB had significantly higher cf-DNA values at day 3
even when patient related factors that might affect cf-DNA
concentration were looked for separately i.e. age, underlying
diseases, alcoholism, severe sepsis, need for inotropic support or
mechanical ventilation, reduced degree of consciousness or high Pitt
bacteraemia scores ($4 points) (Table 2). At day 5, no difference in
cf-DNA between non-survivors and survivors were seen (Table 2).
Cut-off values for cf-DNA in predicting death
In ICU patients, cf-DNA both at days 3 and 5 were found to be
significant predictors for death as analysed by receiver operating
characteristics (ROC) whereas CRP had no significant predictive
value for mortality (Figure 1a). The AUC in the ROC analysis for
the day 3 cf-DNA value in predicting death was 0.71 (95% CI
0.57–0.84, p,0.01) (Figure 1a). The cf-DNA cut-off value at day 3
was 1.99 mg/ml which predicted 90-day mortality with a
sensitivity of 67% and a specificity of 77%. The cf-DNA cut-off
value at day 5 was 1.69 mg/ml with a sensitivity of 63% and a
specificity of 60% and an AUC of 0.71 (95% CI 0.58–0.84,
p,0.01) in predicting death during 90 days follow-up (Figure 1a).
When the ROC-curve analyses were repeated by grouping SAB
patients according to ICU (N = 87) and non-ICU (N = 331)
treatment within the first 3 days instead of the first 7 days the
results were almost identical (data not shown). In non-ICU
patients, the cf-DNA cut-off value at day 3 was 1.57 mg/ml which
predicted 90-day mortality with a sensitivity of 62% and a
specificity of 61%, and the AUC of 0.64 (95% CI 0.55–0.74,
p,0.01) (Figure 1b). The cf-DNA cut-off value at day 5 was
1.49 mg/ml with a sensitivity of 65% and a specificity of 61%, and
the AUC was 0.68 (95% CI 0.59–0.77, p,0.01) in predicting
death for 90 days follow-up.
The patient population was stratified according to the day 3 cf-
DNA cut-off values of 1.99 mg/ml (ICU patients) and 1.57 mg/ml
(non-ICU patients), respectively (Table 3). Factors significantly
associated to higher cf-DNA (.1.99 mg/ml) were septic shock
(p,0.01), mechanical ventilation (p,0.000), reduced conscious-
ness (p,0.01), complicated SAB (p,0.01) as well as high Pitt
bacteraemia score (p,0.000). Moreover, a fatal outcome,
irrespective of death time, was significantly associated to high cf-
DNA values (p,0.000). However, once again, acute or chronic
renal failure, dialysis, acute or chronic liver failure, malignancies
or deep infection foci had no significant association with the higher
cf-DNA (Table 3).
For patients receiving ICU treatment within 7 days of
documented SAB, the factors in univariate analysis associated to
90-day mortality in were age .60 years (OR 3.64, p,0.01), lack
of fatal underlying diseases (OR 0.33, p,0.05), inotropic support
(OR 3.19, p,0.05), mechanical ventilation (OR 2.67, p,0.05),
Pitt bacteraemia scores ($4 points) (OR 3.19, p,0.01) and cf-
DNA .1.99 mg/ml at day 3 (OR 5.24, p,0.000). In multivariate
analysis, only lack of fatal underlying diseases (OR 0.34, CI 95%
0.15–0.77, p,0.05), cf-DNA .1.99 mg/ml at day 3 (OR 3.56, CI
95% 1.69–7.59, p,0.001) and Pitt bacteraemia score $4 points
(OR 4.47, 95% CI 1.94–10.3, p,0.000) were observed to be
significantly associated to mortality (Table 4).
For non-ICU patients, all Table 4 listed univariate parameters
were associated significantly to 90-day mortality whereas in
multivariate analysis lack of fatal underlying diseases (OR 0.26,
p,0.01), corticosteroid use (OR 2.89, p,0.01) and chronic lung
disease (OR 2.45, p,0.05) significantly predicted 90-day outcome.
Among non-ICU patients the cf-DNA cut-off value had no
prognostic impact in multivariate analysis (Table 4). When the cut-
off values for days 3 and 5 in ICU patients were analysed together
in multivariate analysis only the day 3 cf-DNA cut-off value
significantly predicted death (data not shown). Similar results were
obtained when ICU treatment during the first 3 days only were
analysed (data not shown).
Discussion
The main finding of the present study was that plasma cf-DNA
concentrations were higher in SAB patients with high Pitt
bacteraemia scores and ICU treatment as compared to non-ICU
patients. In addition, cf-DNA levels both at days 3 and 5 were
significantly higher in ICU patients with fatal outcome as
compared to survivors irrespective of the death time i.e. if it
occurred during the first week, 28 days or 90 days. The strongest
predictors for a fatal outcome among ICU patients were cf-DNA
at day 3 and Pitt bacteraemia scores$4 points. However, at day 5,
cf-DNA concentration depended more on patient age and
underlying diseases and when they were taken into account in
multivariate analysis cf-DNA at day 5 was not a significant
prognostic marker. To our knowledge, this is the first study where
the prognostic value of cf-DNA of patients with same condition in
ICU and outside it has been compared.
Higher cf-DNA values among critically ill non-survivors as
compared to surviving patients have been reported earlier in many
conditions [17,18,19,20,29,30]. Five studies including 52 to 255
patients with fever of unknown origin, infection, sepsis, severe sepsis,
septic shock or other ICU patients determined cf-DNA at
admission, at 19 h and at 72 h after admission [17,19,20,29,30].
cf-DNA predicted the presence of infection among febrile patients
with AUC of 0.99 with 95% sensitivity and 96% specificity and
Cf-DNA, Pitt Scores, ICU and S.aureus Bacteraemia
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sepsis with AUC of 0.95 and 77% sensitivity and 94% specificity
[20]. For prediction of fatal outcome, the sensitivity of cf-DNA has
ranged from 60% to 92% and the specificity from 67% to 80%
during 0 to 72 hours from ICU admission. [17,19,29]. AUC values
in ROC analysis for fatal outcome in these studies has ranged from
0.70 to 0.88. Recently, cf-DNA determined at ICU admission
predicted mortality among ICU patients with severe sepsis with high
sensitivity of 87% and specificity of 93% and an AUC of 0.97 [30].
Clearly lower predictive cf-DNA values were observed in a larger
study including 580 critically ill patients receiving mechanical
ventilation with cf-DNA determination at ICU admission and at
day 2 [22]. The predictive value for fatal outcome in our study had
an AUC of 0.71, sensitivity of 67% and specificity of 77% which
were lower than the higher end of previously reported values but
comparable to those seen in studies with more variable patient
cohorts [17,19,20,21,22,29]. However, the clinical usefulness of cf-
DNA determinations is still complicated by the use of two different
cf-DNA measurement scales. When cf-DNA is measured straight
from plasma the micro- or nanogram per millilitres (mg/ml or ng/
ml) [17,21] scale is used whereas when cf-DNA quantification is
done with qPCR the results are commonly given as genome
equivalents per millilitres (GE/ml) [19,20,22,29].
The present study differed from the previous studies in several
aspects which certainly has had an impact in lowering the specificity
of the prognostic value of cf-DNA and thus may complicate the
comparison of our results to many previous studies. Firstly, cf-DNA
was measured in relation to documented bacteraemia and not in
relation to ICU admission as in the previous studies
Table 1. Plasma cell-free DNA (cf-DNA) concentrations (mg/ml) at days 3 and 5 from the positive blood culture in 418 patients with
Staphylococcus aureus bacteraemia stratified according to patient demographics, underlying conditions, treatment in intensive
care unit and mortality.
N=418 Factor present2 Factor absent2 p-value1 Factor present3 Factor absent3 p-value1
Demographics
Male sex 262 (63) 1.58 (1.31–1.93) 1.49 (1.26–1.91) NS 1.52 (1.28–1.93) 1.32 (1.17–1.63) ,0.000
Age .60 years 208 (50) 1.54 (1.29–1.99) 1.55 (1.29–1.86) NS 1.50 (1.23–1.98) 1.40 (1.21–1.77) ,0.05
Healthcare-associated 224 (54) 1.54 (1.31–1.92) 1.55 (1.27–1.92) NS 1.46 (1.23–1.79) 1.43 (1.21–1.88) NS
Underlying condition
Healthy or nonfatalA 302 (72) 1.53 (1.29–1.87) 1.58 (1.34–1.99) NS 1.39 (1.20–1.81) 1.56 (1.32–1.92) ,0.01
Alcoholism 47 (11) 1.69 (1.37–2.11) 1.52 (1.29–1.87) NS 1.59 (1.25–2.06) 1.42 (1.21–1.80) ,0.05
Coronary artery disease 109 (26) 1.53 (1.25–1.98) 1.54 (1.30–1.89) NS 1.62 (1.24–2.13) 1.40 (1.21–1.75) ,0.01
Diabetes with complication 105 (25) 1.64 (1.32–2.08) 1.52 (1.29–1.85) NS 1.61 (1.27–2.01) 1.42 (1.21–1.77) ,0.05
Chronic kidney failureB 59 (14) 1.51 (1.29–1.71) 1.54 (1.29–1.94) NS 1.53 (1.35–1.80) 1.41 (1.20–1.84) NS
Dialysis (hemo or peritoneal) 46 (11) 1.51 (1.38–1.72) 1.55 (1.29–1.94) NS 1.53 (1.35–1.78) 1.42 (1.21–1.84) NS
Acute liver failure 5 (1) 1.46 (1.24–2.46) 1.54 (1.29–1.92) NS 1.34 (1.19–1.98) 1.45 (1.22–1.84) NS
Rheumatoid arthritis 24 (6) 1.43 (1.17–1.59) 1.55 (1.29–1.94) NS 1.39 (1.15–1.62) 1.45 (1.23–1.84) NS
Connective tissue disease 31 (7) 1.52 (1.22–2.03) 1.54 (1.29–1.91) NS 1.40 (1.19–1.80) 1.45 (1.22–1.83) NS
Malignancy 60 (14) 1.59 (1.32–2.02) 1.53 (1.29–1.91) NS 1.51 (1.23–1.77) 1.43 (1.21–1.84) NS
PITT Bacteraemia Score
$4 points (high score) 22 (5%) 2.06 (1.56–2.91) 1.53 (1.29–1.88) ,0.000 1.89 (1.59–2.61) 1.42 (1.21–1.81) ,0.001
$3 points 29 (7%) 1.88 (1.47–2.47) 1.53 (1.28–1.87) ,0.01 1.88 (1.54–2.52) 1.42 (1.21–1.80) ,0.000
$2 points 60 (14%) 1.67 (1.37–2.14) 1.53 (1.28–1.87) ,0.05 1.62 (1.34–1.92) 1.41 (1.21–1.81) ,0.05
Treatment in ICU
At documented SAB 65 (16) 1.77 (1.49–2.27) 1.49 (1.27–1.84) ,0.000 1.77 (1.37–2.37) 1.40 (1.19–1.77) ,0.000
Within 3 days 87 (21) 1.74 (1.44–2.19) 1.49 (1.27–1.82) ,0.000 1.64 (1.32–2.26) 1.40 (1.19–1.77) ,0.000
Within 7 days 99 (24) 1.69 (1.41–2.19) 1.49 (1.26–1.81) ,0.000 1.63 (1.31–2.26) 1.40 (1.19–1.76) ,0.000
Infection focus
Any deep infectionC 349 (84) 1.56 (1.32–1.94) 1.37 (1.19–1.74) 0.001 1.49 (1.26–1.92) 1.27 (1.09–1.53) ,0.000
Mortality
At 7 days 16 (4) 2.27 (1.59–3.53) 1.53 (1.29–1.88) ,0.000 1.95 (1.51–2.92) 1.42 (1.21–1.82) ,0.01
At 28 days 52 (12) 1.75 (1.44–2.52) 1.52 (1.27–1.85) ,0.000 1.72 (1.42–3.01) 1.40 (1.20–1.78) ,0.000
At 90 days 73 (18) 1.74 (1.45–2.37) 1.49 (1.27–1.83) ,0.000 1.70 (1.41–2.56) 1.39 (1.19–1.78) ,0.000
1Mann-Whitney U-test.
2At day 3 from the positive blood culture.
3At day 5 from the positive blood culture.
AAccording to McCabe and Jackson [33].
BChronically elevated serum creatinine (.180 mmol/l).
CDuring the 90 days follow-up.
Values are expressed as N (%), unless otherwise stated, or as median (quartiles). NS = non-significant.
doi:10.1371/journal.pone.0087741.t001
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[17,19,22,29,30]. Secondly, cf-DNA was measured also later i.e. at
day 5 as compared to previous studies where the last measurement
was made at 72 hours from ICU admission. Thirdly, we used Pitt
bacteraemia scores and we did not determine Acute Physiology and
Chronic Health Evaluation II (APACHE II) scores [13] or
sequential organ failure assessment (SOFA) scores [14] which have
been included in most studies evaluating the prognostic value of cf-
DNA among ICU patients [17,18,19,20,21,22,29,30]. However,
Pitt bacteraemia scoring has been demonstrated to predict mortality
among ICU sepsis patients more accurately as compared to
APACHE II [12] and Pitt bacteraemia scores have previously been
applied in patients with SAB [15,16].
The present study demonstrated strong significant association
between cf-DNA, Pitt bacteraemia scores and outcome among
ICU patients. High Pitt bacteraemia scores correlated with high
cf-DNA and with fatal outcome. The time point of cf-DNA
measurements were not correlated to clinical deterioration i.e.
ICU admission but to a fixed time point of the disease which is a
novelty of this study but has certainly led to lower cf-DNA
concentrations in patients who deteriorated later. Even without
ICU risk scores it is evident that a part of most severely ill patients
have been missed in the present study since we only had 4% of
ICU patients classified as severe sepsis whereas in another previous
study with highest specificity and sensitivity for the prognostic
values of cf-DNA they had 100% of patients with severe sepsis and
APACHE points over 20 [30]. The low 12% mortality within 28
days in our patient cohort was at the lower level as compared to
previously published in SAB and also confirms that some severely
ill patients have been missed [6,7,8]. However, in our patient
cohort 24% of patients needed ICU treatment which corresponds
well with the proportion described in other studies of 11-32%
[9,35,36]. Out of ICU patients, 8% deceased within one week of
bacteraemia. This mortality rate was far lower than those in earlier
studies of 25–34% [17,29] whereas another former Finnish study
had low ICU mortality rate of 13% [19]. All these facts aim to
lower the power of the present study and still cf-DNA was
observed to be a significant prognostic marker specifically in SAB
patients treated in ICU.
When all prognostic markers were accounted for, Pitt bacter-
aemia scores $4 points and day 3 cf-DNA cut-off value were the
strongest factors predicting fatal outcome among the ICU patients
with McCabes’ healthy-nonfatal classification being the third
parameter with significant prognostic impact. The same result was
achieved when ICU treatment within the first 3 or 7 days were
looked for. This is in line with data from the study where only
patients with high (.20) APACHE scores were included [30].
Male gender and alcoholism have earlier been connected to higher
baseline cf-DNA values [21] whereas some studies have found no
connection between cf-DNA and age or gender [18,29]. Among
ICU patients, non-survivors had significantly higher cf-DNA at
day 3 whereas non-significant difference was seen at day 5. This
finding suggests that early apoptosis in SAB in ICU treated
patients might be one of the factors leading to fatal outcome.
We included only bacteraemia due to S. aureus which reduces
the number of possible variables. Due to low prevalence of MRSA
in Finland all patients received effective antimicrobial therapy and
it was instituted to all patients on the day when the positive blood
culture was drawn. This also reduced one factor difficult to control
when evaluating the usefulness of a new biomarker. Delayed
effective antimicrobial therapy has been reported to be one of the
main risk factors for poor prognosis [37]. MRSA is associated with
poor prognosis and delay in effective antibiotic therapy [6,38,39].
Vancomycin treatment is reported to result in higher risk for
recurrence and persistence of SAB when compared to treatment
with the staphylococcal penicillin cloxacillin [40]. The well
controlled prognostic factors made it possible to observe variables
that affect cf-DNA levels.
We observed that patients in ICU had clearly higher cf-DNA
levels as compared to non-ICU patients which could be expected
as cf-DNA values have generally been reported to correlate well
with the SOFA and APACHE scores in critically ill patients
[17,18,19,20,30]. Also in the present study, a strong correlation
between high cf-DNA levels and high Pitt bacteraemia scores was
Table 2. Plasma cell-free DNA (cf-DNA) concentrations (mg/ml) at days 3 and 5 from the positive blood culture in 99 patients with
Staphylococcus aureus bacteraemia (SAB) treated in intensive care unit (ICU) within 7 days of documented bacteraemia.
ICU survivors2 ICU non-survivors2 p-value1 ICU survivors13 ICU non-survivors3 p-value1
Background characteristics
Age .60 years 1.62 (1.37–2.16) 3.97 (2.55–9.46) ,0.01 1.57 (1.31–2.46) 2.27 (1.59–3.01) NS
Healthy or nonfatal diseaseA 1.67 (1.40–2.12) 2.37 (1.80–7.92) ,0.05 1.53 (1.29–1.93) 2.27 (1.52–3.01) NS
Alcoholism 1.68 (1.37–2.30) 5.96 (2.37–11.0) ,0.05 1.81 (1.34–1.93) 2.96 (1.70–2.73) NS
Disease severity at documented
SAB
Severe sepsis 1.69 (1.40–2.11) 3.94 (1.91–7.22) ,0.05 1.64 (1.31–1.88) 2.66 (1.72–3.48) NS
Inotropic support 1.77 (1.50–2.23) 3.05 (2.01–5.96) ,0.05 1.63 (1.29–1.97) 2.31 (1.89–3.33) NS
Mechanical ventilation 1.82 (1.43–2.30) 3.60 (1.91–7.22) ,0.05 1.90 (1.48–2.66) 2.64 (1.71–3.48) NS
Reduced degree of consciousnessB 1.68 (1.37–2.38) 3.05 (2.01–5.96) ,0.05 1.76 (1.38–2.61) 2.31 (1.89–3.23) NS
PITT Bacteraemia Score $4 points 1.83 (1.42–2.42) 3.05 (2.01–5.96) ,0.05 1.76 (1.45–2.45) 2.31 (1.89–3.33) NS
Complicated SAB 1.66 (1.39–2.14) 3.07 (2.09–5.68) ,0.01 1.59 (1.29–2.12) 2.29 (1.58–3.17) NS
1Mann-Whitney U-test.
2At day 3 from the positive blood culture.
3At day 5 from the positive blood culture.
AAccording to McCabe and Jackson [33].
BUnconsciousness or somnolent.
Patients are divided according to survivors (N = 91) and non-survivors (N = 8) at 7 days follow-up. Values are given as median (quartiles). NS = non-significant.
doi:10.1371/journal.pone.0087741.t002
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seen. In a previous study with only bacteraemic patients with
various pathogens (S. aureus, Streptococcus pneumoniae, b-hemolytic
streptococcae or Escherichia coli) higher cf-DNA values in ICU
treated patients was reported but the cut-off values were not
studied separately [21]. In the present study the difference in cf-
DNA cut-off value between ICU and non-ICU was more evident
at day 3 as compared to day 5. Furthermore, in non-ICU patients,
cf-DNA was not an independent predicting factor for mortality
suggesting that cf-DNA might have its best clinical use in
predicting outcome early among ICU patients.
In the present study, acute or chronic renal or liver failure or
elevated alanine-aminotransferase liver values were not associated
Figure 1. a: Receiver operating characteristic (ROC) curves for cf-DNA and C-reactive protein (CRP) for predicting 90-day mortality in patients with
Staphylococcus aureus bacteraemia (SAB) treated in intensive care unit (ICU) during 7 days of documented bacteraemia (N= 99). The area under the
curve (AUC) for the day 3 cf-DNA was 0.71 (95% CI 0.57–0.84) (p,0.01) with cut-off value of 1.99 mg/ml with sensitivity of 67% and specificity of 77%.
For day 5 cf-DNA, the AUC was 0.71 (0.58–0.84) (p,0.01) with cut-off value of 1.69 mg/ml with sensitivity of 63% and specificity of 60%. The
corresponding AUC for day 3 CRP was 0.46 (0.32–0.59) (p = 0.55) and for day 5 CRP 0.47 (0.34–0.61) (p = 0.67). b: Receiver operating characteristic
(ROC) curves for cf-DNA and CRP for predicting 90-day mortality in patients with Staphylococcus aureus bacteraemia (SAB) without treatment in
intensive care unit (ICU) during 7 days of documented bacteraemia (N= 319). The area under the curve (AUC) for day 3 cf-DNA was 0.64 (95% CI 0.55–
0.74) (p,0.01) and cut-off value of 1.57 mg/ml with sensitivity of 62% and specificity of 61%. For day 5 cf-DNA, the AUC was 0.68 (0.59–0.77) (p,0.01)
with cut-off value of 1.49 mg/ml with sensitivity of 65% and specificity of 61%. The corresponding AUC for day 3 CRP was 0.46 (0.36–0.57) (p = 0.48)
and for day 5 CRP 0.51 (0.41–0.62) (p = 0.80).
doi:10.1371/journal.pone.0087741.g001
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to higher cf-DNA concentrations. Experimental animal studies
indicate that liver and kidneys are responsible for cf-DNA
clearance although the exact clearance process is unknown [41].
One study reported higher cf-DNA levels among critically ill
patients with acute renal failure requiring renal support [17]
whereas in another study no difference in DNA concentrations
between healthy controls and predialysis patients was observed
[42]. The exact clearance mechanism for cf-DNA requires further
investigations and currently the impact of acute or chronic liver or
renal failure on cf-DNA levels remains to be established.
Along with the cell-free DNA as a biomarker, procalcitonin and
interleukin-10 have been investigated as promising biomarkers for
patients with bacteraemia or sepsis. Recently, procalcitonin was
presented as a predictor for endocarditis in SAB [43] and
proposed to be a superior predictor for sepsis [20,44]. To the best
of our knowledge, no reports have investigated the prognostic
value of procalcitonin solely in SAB patients. Interleukin-10 was
recently demonstrated to be an independent mortality predictor in
SAB patients with survivors having normal interleukin-10 levels
[45] but interleukin-10 has been demonstrated to be a weaker
predictor of ICU mortality among sepsis patients as compared to
cf-DNA [30]. Further investigations are required to determine the
relationship between cf-DNA, procalcitonin and interleukin-10 as
biomarkers for bacteraemia and sepsis patients.
In conclusion, this study is the first one to demonstrate that cf-
DNA levels significantly correlated with higher Pitt bacteraemia
Table 3. Underlying conditions, severity of illness and mortality in 418 patients with Staphylococcus aureus bacteraemia stratified
according to the cf-DNA cut-off value at day 3 for ICU (1.99 mg/ml) and non-ICU (1.57 mg/ml) patients.
.1.991 ,1.992 OR (95% CI) p-value .1.573 ,1.574 OR (95% CI p-value
Background characteristics
Male sex 52 (60) 210 (63) 0.89 (0.55–1.45) NS 126 (68) 136 (58) 1.52 (1.02–2.28) ,0.05
Healthy or nonfatalA 45 (52) 179 (54) 0.94 (0.58–1.51) NS 127 (68) 175 (75) 0.73 (0.47–1.12) NS
Coronary artery disease 25 (29) 84 (25) 1.21 (0.71–2.05) NS 49 (26) 60 (26) 1.04 (0.67–1.61) NS
Chronic renal failureB 9 (10) 50 (15) 0.66 (0.31–1.40) NS 25 (13) 34 (14) 0.92 (0.52–1.59) NS
Chronic liver failure 8 (9) 57 (17) 0.49 (0.23–1.08) NS 22 (12) 43 (18) 0.59 (0.33–1.04) NS
Connective tissue diseaseC 10 (11) 38 (11) 1.01 (0.49–2.14) NS 17 (9) 31 (13) 0.66 (0.35–1.23) NS
Malignancy 14 (16) 46 (14) 1.21 (0.63–2.32) NS 29 (15) 31 (13) 1.21 (0.70–2.09) NS
Severity of illness
SIRS-Sepsis 54 (63) 177 (53) 1.48 (0.91–2.41) NS 114 (61) 117 (50) 1.59 (1.08–2.36) NS
Severe sepsis 2 (2) 13 (4) 0.58 (0.13–2.54) NS 8 (4) 7 (3) 1.46 (0.52–4.10) NS
Septic shock 7 (8) 5 (2) 5.79 (1.79–18.7) ,0.01 10 (5) 2 (1) 6.60 (1.43–30.5) ,0.01
Mechanical ventilation 9 (10) 7 (2) 5.43 (1.96–15.0) ,0.000 11 (5) 5 (2) 2.88 (0.98–8.45) ,0.05
Reduced consciousnessD 10 (11) 14 (4) 2.99 (1.28–6.98) ,0.01 12 (6) 12 (5) 1.28 (0.56–2.91) NS
Acute dialysis need 1 (1) 4 (1) 0.97 (0.11–8.74) NS 3 (1) 2 (1) 1.90 (0.32–11.5) NS
Acute liver failure 2 (2) 3 (1) 2.61 (0.43–15.9) NS 2 (1) 3 (1) 0.84 (0.14–5.07) NS
ALAT elevation62E 4 (4) 12 (4) 1.08 (0.33–3.55) NS 7 (4) 9 (4) 0.92 (0.33–2.58) NS
Complicated SAB 70 (81) 283 (85) 5.03 (1.53–16.5) ,0.01 164 (88) 189 (81) 1.78 (1.01–3.12) ,0.05
PITT Bacteraemia Score
$4 points (high score) 11 (12) 11 (3) 4.28 (1.79–10.2) ,0.000 15 (8) 7 (3) 2.85 (1.14–7.14) ,0.05
$3 points 12 (14) 17 (5) 3.00 (1.38–6.56) ,0.01 18 (10) 11 (5) 2.18 (1.00–4.73) ,0.05
$2 points 18 (21) 42 (12) 1.83 (0.99–3.37) ,0.05 33 (18) 27 (11) 1.66 (0.96–2.87) NS
Deep infection fociF
Any deep infection foci 75 (87) 274 (83) 1.44 (0.72–2.89) NS 161 (87) 188 (80) 1.61 (0.94–2.75) NS
Mortality
Died within 7 days 10 (11) 6 (2) 7.15 (2.52–20.3) ,0.000 3 (1) 13 (5) 5.79 (1.63–20.7) ,0.01
Died within 28 days 23 (26) 29 (9) 4.81 (2.07–7.06) ,0.000 34 (18) 18 (8) 2.69 (1.46–4.94) ,0.01
Died within 90 days 31 (36) 42 (12) 3.89 (2.25–6.72) ,0.000 49 (26) 24 (10) 3.14 (1.84–5.35) ,0.000
1N= 86,
2N= 332,
3N= 185,
4N= 233.
AAccording to McCabe and Jackson [33].
BChronically elevated creatinine (.180 mmol/l).
CIncludes rheumatoid arthritis.
DUnconsciousness or somnolent.
ESerum Alanine-aminotransferase elevation .2 times general reference.
FInfection foci during 90 days follow-up.
Values are expressed as N (%). OR = odds ratio (95% confidence intervals) NS = non-significant.
doi:10.1371/journal.pone.0087741.t003
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scores and ICU treatment among SAB patients as compared to
non-ICU SAB patients. Among ICU patients, when all prognostic
markers were accounted for, high Pitt bacteraemia scores and day
3 cf-DNA cut-off value were the strongest factors significantly
predicting death. cf-DNA had no prognostic value among non-
ICU SAB patients.
Key messages
N Plasma cell-free DNA correlated with high Pitt bacteraemia
score and was higher in SAB patients treated in ICU as
compared to non-ICU patients.
N Plasma cell-free DNA at day 3 and 5 were significantly higher
in ICU patients with fatal outcome irrespective of death time.
N High Pitt bacteraemia scores ($4 points) and day 3 plasma
cell-free DNA were the only factors that significantly predicted
outcome in SAB patients with ICU treatment.
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